pharma news

News

White jigsaw pieces on a yellow background

Lilly strikes $1.9bn kidney disease alliance with Ascidian

In its third big licensing deal of the week, Eli Lilly has tapped RNA-editing specialist Ascidian for kidney disease therapies in a $1.9bn alliance.

News

ASCO26: Celcuity punished as trial disappoints investors

Celcuity is still confident it has a winner with its breast cancer treatment, gedatolisib, but investors seem less convinced by new VIKTORIA-1 data.

News

FDA prior knowledge guide seeks to speed cell, gene therapy

The FDA has laid out a framework to use 'prior knowledge' on manufacturing, non-clinical, and clinical data to support cell and gene therapy filings.

News

ASCO26: In vivo CAR-Ts in the spotlight

Data at ASCO on in vivo CAR-Ts from Kelonia and Legend add to the excitement about the emerging therapy class in both blood cancers and solid tumours.

News

ASCO26: After negative adcomm, AZ builds case for oral SERD

AstraZeneca showcases new data from the SERENA-6 data of camizestrant in breast cancer that it hopes will get FDA's review of the drug back on track.

News

Abivax slides on phase 3 data in ulcerative colitis

Shares in Abivax have tumbled after it announced phase 3 data with ulcerative colitis drug obefazimod that included several cases of cancer.

Lilly strikes $1.9bn kidney disease alliance with Ascidian

ASCO26: Celcuity punished as trial disappoints investors

FDA prior knowledge guide seeks to speed cell, gene therapy

ASCO26: In vivo CAR-Ts in the spotlight

ASCO26: After negative adcomm, AZ builds case for oral SERD

Abivax slides on phase 3 data in ulcerative colitis

Grail cancer test gets lukewarm backing from FDA adcomm

Discover a new era of healthcare panel engagement: Grounded ...

pharma news

Editor's Picks